Gossamer Bio (GOSS) Projected to Post Earnings on Tuesday

Gossamer Bio (NASDAQ:GOSS - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Tuesday, March 4th. Analysts expect Gossamer Bio to post earnings of ($0.15) per share and revenue of $7.02 million for the quarter.

Gossamer Bio Price Performance

GOSS traded up $0.04 during midday trading on Friday, hitting $1.23. 1,472,015 shares of the company traded hands, compared to its average volume of 1,562,936. The business has a 50 day simple moving average of $1.06 and a two-hundred day simple moving average of $0.94. Gossamer Bio has a 52-week low of $0.50 and a 52-week high of $1.60. The company has a market capitalization of $278.72 million, a price-to-earnings ratio of -3.84 and a beta of 1.81. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64.

Institutional Investors Weigh In On Gossamer Bio

An institutional investor recently raised its position in Gossamer Bio stock. Bank of America Corp DE increased its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 107.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 84,788 shares of the company's stock after acquiring an additional 43,866 shares during the quarter. Bank of America Corp DE's holdings in Gossamer Bio were worth $77,000 at the end of the most recent reporting period. Institutional investors own 81.23% of the company's stock.

Remove Ads

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Gossamer Bio in a research note on Thursday, January 30th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $9.20.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.